/CEMI

CEMI Stock - Chembio Diagnostics, Inc.

Q: What is the analyst price target for CEMI?

Analyst price target information is not currently available for CEMI.

Q: What is CEMI's market cap?

Market capitalization information is not currently available for CEMI.

Healthcare|Medical - Diagnostics & Research|NASDAQ

$0.46+0.22%

+$0.00 (+0.22%) • Apr 27

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CEMI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.86

52W High$1.24

52W Low$0.19

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$48.34M	$36.93M	$30.45M	$34.46M	$33.41M
Gross Profit	$9.76M	$2.43M	$6.58M	$12.07M	$11.98M
Gross Margin	20.2%	6.6%	21.6%	35.0%	35.9%
Operating Income	$-20,401,861	$-24,005,385	$-21,950,485	$-12,607,125	$-7,645,023
Net Income	$-23,290,657	$-33,903,529	$-25,521,328	$-13,675,129	$-7,865,649
Net Margin	-48.2%	-91.8%	-83.8%	-39.7%	-23.5%
EPS	$-0.96	$-1.40	$-1.34	$-0.81	$-0.54

Company Overview

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Visit Website

Earnings History & Surprises

CEMI

Beat Rate

29%

Last 17 quarters

Avg Surprise

-10.8%

EPS vs Estimate

Beats / Misses

5/11

1 met exactly

Latest EPS

$-0.02

Q1 2023

EPS Surprise History

Q2 21

+26.7%

$-0.22vs$-0.30

Q3 21

+7.9%

$-0.35vs$-0.38

Q4 21

-9.5%

$-0.23vs$-0.21

Q1 22

-39.1%

$-0.32vs$-0.23

Q2 22

-38.1%

$-0.29vs$-0.21

Q3 22

No data

Q4 22

No data

Q1 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2023	Mar 29, 2023	—	$-0.02	—	—
Q4 2022	Nov 3, 2022	—	$-0.21	—	—
Q3 2022	Aug 4, 2022	—	$-0.23	—	—
Q2 2022	May 5, 2022	$-0.21	$-0.29	-38.1%	✗ MISS
Q1 2022	Mar 3, 2022	$-0.23	$-0.32	-39.1%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.21	$-0.23	-9.5%	✗ MISS
Q3 2021	Aug 5, 2021	$-0.38	$-0.35	+7.9%	✓ BEAT
Q2 2021	May 6, 2021	$-0.30	$-0.22	+26.7%	✓ BEAT
Q1 2021	Mar 11, 2021	$-0.28	$-0.35	-25.0%	✗ MISS
Q4 2020	Nov 5, 2020	$-0.24	$-0.28	-16.7%	✗ MISS
Q3 2020	Aug 6, 2020	$-0.41	$-0.40	+2.4%	✓ BEAT
Q2 2020	May 4, 2020	$-0.22	$-0.25	-13.6%	✗ MISS
Q1 2020	Mar 12, 2020	$-0.25	$-0.23	+8.0%	✓ BEAT
Q4 2019	Nov 7, 2019	$-0.19	$-0.22	-15.8%	✗ MISS
Q3 2019	Aug 6, 2019	$-0.16	$-0.19	-18.8%	✗ MISS
Q2 2019	May 1, 2019	$-0.14	$-0.14	0.0%	= MET
Q1 2019	Mar 7, 2019	$-0.17	$-0.21	-23.5%	✗ MISS
Q4 2018	Nov 8, 2018	$-0.15	$-0.16	-6.7%	✗ MISS
Q3 2018	Aug 8, 2018	$-0.07	$-0.12	-71.4%	✗ MISS
Q2 2018	May 9, 2018	$-0.10	$-0.05	+50.0%	✓ BEAT

Frequently Asked Questions about CEMI

What is CEMI's current stock price?

Chembio Diagnostics, Inc. (CEMI) is currently trading at $0.46 per share. The stock has moved +0.22% today.

What is the analyst price target for CEMI?

No analyst price targets are currently available for this stock.

What sector is Chembio Diagnostics, Inc. in?

Chembio Diagnostics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.

What is CEMI's market cap?

Chembio Diagnostics, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.

Does CEMI pay dividends?

No, Chembio Diagnostics, Inc. does not currently pay a dividend to shareholders.